The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact

References

• Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418–5422.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–5417.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302(24):1347–1349.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749–757.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(9):1606–1610.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia. 2013;27(4):947–953.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27(4):941–946.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Moulopoulos LA, Terpos E, et al. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia. 2014;28(12):2402–2403.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Usmani S, Rajkumar SV, et al., International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302–e12.
   PubMed Web of Science ®Google Scholar
• Zamagni E, Nanni C, Gay F, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417–422.
   PubMed Web of Science ®Google Scholar
• Sørrig R, Klausen TW, Salomo M, et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol. 2016;97(3):303–309.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–2592.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.
   PubMedGoogle Scholar
• Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680–685.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31(1):130–135.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123(4):631–636.
   PubMed Web of Science ®Google Scholar
• Ravi P, Kumar S, Larsen JT, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6(7):e454.
   PubMedGoogle Scholar
• Atrash S, Robinson M, Slaughter D, et al. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J. 2018;8(11):107.
   PubMedGoogle Scholar
• Fernandez de Larrea C, Isola I, Pereira A, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia. 2018;32(6):1427–1434.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Ravi P, Rajkumar SV, et al. Response to ‘Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.’ Leukemia. 2018;32(9):2083–2085.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31(34):4325–4332.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738–1744.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123(1):78–85.
   PubMed Web of Science ®Google Scholar
• Khan R, Dhodapkar M, Rosenthal A, et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015;100(9):1214–1221.
   PubMed Web of Science ®Google Scholar
• Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia. 2014;28(9):1902–1908.
   PubMed Web of Science ®Google Scholar
• Siontis B, Kumar S, Dispenzieri A, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015;5(10):e364.
   PubMedGoogle Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–789.
   PubMed Web of Science ®Google Scholar
• Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;54(10):2215–2218.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Kumar S, Dimopoulos MA, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.
   PubMed Web of Science ®Google Scholar
• Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785–795.
   PubMed Web of Science ®Google Scholar
• Visram A, Soof C, Rajkumar SV, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021;11(6):120.
   PubMed Web of Science ®Google Scholar
• Bustoros M, Sklavenitis-Pistofidis R, Park J, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020;38(21):2380–2389.
   PubMed Web of Science ®Google Scholar
• Oben B, Froyen G, Maclachlan KH, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021;12(1):1861.
   PubMed Web of Science ®Google Scholar
• Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma group of Western Sweden. Eur J Haematol. 1993;50(2):95–102.
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma. Br J Cancer. 2000;82(7):1254–1260.
   PubMed Web of Science ®Google Scholar
• Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003;14(10):1468–1476.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Rocci L, et al. Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol. 2003;14(5):806–807.
   PubMed Web of Science ®Google Scholar
• Gordon S, Helfrich MH, Sati HI, et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol. 2002;119(2):475–483.
   PubMed Web of Science ®Google Scholar
• Corso A, Ferretti E, Lazzarino M. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology. 2005;10(3):215–224.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma. 2011;52(5):771–775.
   PubMed Web of Science ®Google Scholar
• Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7):1588–1595.
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21(1):16–19.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Semin Hematol. 2003;40(4 Suppl 4):17–22.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013;27(1):220–225.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–1136.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Hernandez MT, Giraldo P, et al. Long term follow-up on the tretament of high risk smoldering myeloma with lenalidomide plus low dose dex (Rd) (phase III spanish trial): persistent benefit in overall survival. Blood. 2014;124(21):3465.
   Web of Science ®Google Scholar
• Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019;JCO1901740.
   Web of Science ®Google Scholar
• Kazandjian D, Hill E, Morrison C, et al. Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): a Phase 2 clinical and correlative study. Blood. 2020;136(Supplement 1):43–45.
   Google Scholar
• Mateos M-V, Martinez-Lopez J, Otero P, et al., Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood. 2019;134(Supplement_1):781.
   Google Scholar
• Samur M, Roncador M, Aktas Samur A, et al. High-dose melphalan significantly increases mutational burden in multiple myeloma cells at relapse: results from a randomized study in multiple myeloma. Blood. 2020;136(Supplement 1):4–5.
   PubMedGoogle Scholar
• Krishnan AY, Mei M, Sun CL, et al. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(2):260–265.
   PubMedGoogle Scholar
• Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119(12):2731–2737.
   PubMed Web of Science ®Google Scholar
• Bustoros M, Liu C-J, Reyes K, et al. Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood. 2018;132(Suppl 1):804.
   PubMedGoogle Scholar
• Liu C-J, Ghobrial IM, Bustoros M, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood. 2018;132(Suppl 1):154.
   Google Scholar
• Manasanch EE, Han G, Zhang Z, et al. Extensive changes of the immune microenvironment are associated with progression from precursor stages to multiple myeloma. Blood. 2020;136(Supplement 1):37–38.
   Google Scholar
• Lopes R, Caetano J, Ferreira B, et al. The immune microenvironment in multiple myeloma: friend or foe? Cancers (Basel). 2021;13(4):625.
   Web of Science ®Google Scholar
• Hofmeister CC, Chari A, Cohen Y, et al. Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): centaurus, a randomized, open-label, multicenter phase 2 study. Blood. 2017;130(Suppl 1):510.
   Google Scholar
• Landgren O, Cavo M, Chari A, et al. Updated results from the phase 2 centaurus study of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM). Blood. 2018;132(Supplement 1):1994.
   PubMedGoogle Scholar
• Manasanch E, Jagannath S, Lee H, et al. A multicenter Phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM). Blood. 2019;134(Supplement_1):3116.
   Google Scholar
• Jagannath S, Laubach J, Wong E, et al. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018;182(4):495–503.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Das R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 2015;126(22):2475–2478.
   PubMed Web of Science ®Google Scholar
• Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400–2408.
   PubMed Web of Science ®Google Scholar
• Brighton TA, Khot A, Harrison SJ, et al. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clin Cancer Res. 2019;25(13):3772.
   PubMed Web of Science ®Google Scholar
• Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020;34(7):1840–1852.
   PubMed Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746–754.
   PubMed Web of Science ®Google Scholar
• Mailankody S, Kazandjian D, Korde N, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv. 2017;1(22):475–478.
   Web of Science ®Google Scholar